ALK and non-small cell lung carcinoma: Several studies in Western countries have reported that NSCLC with EGFR-mutated or ALK-rearranged phenotypes have disappointing clinical outcomes, with lower objective response rates (ORRs) and shorter progression-free survival (PFS) to PD-1 /PD-L1 inhibitors16.